Patient Data Data is evaluated to determine possible condition and appropriate interventions. Complete the diagram by dragging from the choices area to specify which condition the client is most likely experiencing, two actions the nurse should take to address that condition, and two parameters the nurse should monitor to assess the client's progress.

Condition: Serotonin syndrome Actions to Take: Discontinue antidepressant Apply cooling blanket Parameters to Monitor: Temperature Hydration Rationale: • Serotonin syndrome: The client exhibits classic signs of serotonin syndrome, including altered mental status, agitation, diaphoresis, myoclonus, intermittent rigidity, tachycardia, hypertension, nausea, and diarrhea. The recent ingestion of phenelzine (an MAOI) on top of ongoing paroxetine (an SSRI) creates a high-risk drug interaction, precipitating excess serotonergic activity. • Suicidal ideation: Although the client has a history of major depressive disorder, there is no evidence of active suicidal thoughts or behaviors in this scenario. The acute onset of neurological and autonomic symptoms is more consistent with a toxic reaction rather than a psychiatric crisis. Suicide precautions are not indicated here. • Tuberculosis: There is no evidence of cough, sputum production, night sweats, or weight loss, and lung sounds are clear. The client’s acute presentation, including rigidity, myoclonus, and hyperthermia, does not align with a chronic infectious process like tuberculosis. • Acute stress disorder: Symptoms of acute stress disorder typically follow a traumatic event and include re-experiencing, avoidance, and hyperarousal, rather than acute autonomic instability and neuromuscular changes. The client’s presentation is linked to a pharmacologic cause rather than psychological trauma. • Discontinue antidepressant: Immediate discontinuation of serotonergic medications is critical to prevent further accumulation of serotonin, which can worsen the syndrome. Stopping both the MAOI (phenelzine) and the SSRI (paroxetine) reduces the risk of escalating toxicity and is a primary intervention in managing serotonin syndrome. • Apply cooling blanket: The client’s hyperthermia (temperature rising to 102.4°F/39.1°C) reflects the severe metabolic effects of serotonin syndrome. Applying a cooling blanket helps lower core body temperature and prevents complications such as rhabdomyolysis, seizures, or multiorgan failure. Temperature control is a key supportive measure in acute management. • Place on contact isolation: Contact isolation is unnecessary because there is no infectious disease risk. Serotonin syndrome is a toxic-medication reaction, not transmissible, so isolation precautions do not contribute to safety or management. • Place on suicide watch: While monitoring mental status is important, suicide watch is not indicated because there is no evidence of self-harm intent in the acute presentation. The priority is stabilizing the client’s physiologic state, not psychiatric containment. • Apply wrist restraints: Physical restraints are generally reserved for situations in which the client poses imminent risk to self or staff. While the client is combative, sedation with diazepam is already ordered and is the preferred method to manage agitation in serotonin syndrome. Restraints do not treat the underlying condition. • Temperature: Monitoring temperature is essential to assess the severity of hyperthermia and the client’s response to interventions. Persistent or rising temperature may indicate worsening serotonin toxicity or failure of cooling measures, guiding further treatment such as antipyretics or sedation. • Hydration: Maintaining adequate hydration is necessary to prevent renal complications from rhabdomyolysis and to support cardiovascular stability. IV fluids help replace losses from diaphoresis, vomiting, or diarrhea and assist in the clearance of excess serotonin and metabolites. • Sputum changes: There are no respiratory secretions or pulmonary infections present. Monitoring sputum would not provide useful information in managing serotonin syndrome, making it irrelevant in this scenario. • Isolation precautions: No infectious process is suspected, so implementing isolation precautions does not affect care or outcome. The client’s symptoms are due to a toxic pharmacologic interaction, not transmissible disease. • Affect: While mental status changes are present, affect monitoring alone does not provide measurable progress regarding physiologic stabilization in serotonin syndrome. Vital signs, temperature, and hydration are more critical parameters to assess recovery.